An interventional study of Physical Activity Program in Metastatic Gastrointestinal Cancer and Physical Activity, sponsored by Dana-Farber Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-12.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care
Among 12 studies in Gastrointestinal Neoplasms by Dana-Farber Cancer Institute — 2 open to participants now, 3 under way, none of them phase 3. Gastrointestinal Neoplasms · Dana-Farber Cancer Institute.
Among the 12 studies in Gastrointestinal Neoplasms by Dana-Farber Cancer Institute, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 10 with no phase, and was the 3rd registered.
695 studies on the registry are indexed under Gastrointestinal Neoplasms; 209 are open to participants now.
Browse Gastrointestinal Neoplasms studies →2 of the 12 studies in Gastrointestinal Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Dana-Farber Cancer Institute · Sites in United States
By country, each count listing its studies:
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1
First in 2007; this study’s year is marked. 1 started in 2017.
This study's enrollment of 20 is below the median of 74 across 494 interventional studies indexed under Gastrointestinal Neoplasms.
Median enrollment 123 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dana-Farber Cancer Institute is the lead sponsor of 834 studies on the registry; 122 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
1 of the studies in Gastrointestinal Neoplasms by Dana-Farber Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04674267Dana-Farber Cancer InstituteResilience and Equity in Aging, Cancer, and Health (REACH) | 2026-12-31 |
Among the 12 studies in Gastrointestinal Neoplasms by Dana-Farber Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research study is evaluating the ability for people with metastatic gastrointestinal cancer to participate in a physical activity program.
The physical activity program is 12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Start of trial:
Phase 1 (most strict) Eligibility criteria include:
Phase 2 (less restrictive) Eligibility criteria will loosen:
-- The minimum age from greater than 65, to greater than 55;
Phase 3 (least restrictive) Eligibility criteria will add:
-- The minimum age from greater than 55, to greater than 18.
Known or suspected brain or other central nervous system ;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week. * At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity. * Exercise Trainer --A exercise trainer will be assigned to design a physical activity program.
Other: Physical Activity Program
12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
Rate of Accrual
Recruit 20 patients within 12 months
Time frame: 12 months
Number of participants that adhered to physical activity program
Demonstrate that at least 50% of patients adhered to at least 50% of the prescribed physical activity program.
Time frame: 12 Weeks
Rate of Retention
Proportion of participants who complete the study
Time frame: 12 Weeks
Number of participants that complete assessment procedures
Physical function testing and questionnaire collection
Time frame: 12 Weeks
Number of participants with adverse events
Falls, hospitalizations, and musculoskeletal injury
Time frame: 12 Weeks
Plan to share: No
Ran from Dec 2017 to primary completion in Jan 2019, 13 months.
Of 153 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's 13 months is below that.
Counting every sponsor, half of 163 studies reached it within 35 months; a quarter within 17 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →